ProTrials Research, Inc.TM, a leader in the clinical research organization industry, today announced the company made the 2008 Inc. 5000 list of the fastest-growing private companies in the United States.
ProTrials Makes The Inc. 5000, Reflecting Three-Year Sales Growth
ProTrials selected as one of the fastest-growing private companies in the U.S.
Mountain View, CA – August 28, 2008 – ProTrials Research, Inc.TM, a leader in the clinical research organization industry, today announced the company made the 2008 Inc. 5000 list of the fastest-growing private companies in the United States. With 125 percent sales growth over the last three years, The Inc. 5000 ranked ProTrials at number 2,858 and number 40 in the top 50 businesses in the San Jose-Sunnyvale-Santa Clara, CA area.
“Our ranking on this prestigious list for the second straight year was a direct result of the unrivaled service we provide our customers,” said Jodi Andrews, ProTrials co-founder and CEO. “Because we are hired clinical trial help, the recent revenue increase we’ve witnessed at ProTrials is a testament to the quality of work we provide and the relationships we’ve built with our clients.”
The Inc. 5000 is a comprehensive look at American entrepreneurs. To be considered, companies must be U.S.-based and privately held, for profit, independent – not subsidiaries or divisions of other companies – and, as of December 31, 2007, have achieved at least $200,000 in revenue in 2004, and $2 million in 2007. The 5000 companies that made the list reported aggregate revenue of $185 billion. Complete results of the Inc. 5000, including company profiles and a list of the fastest-growing companies that can be sorted by industry and region can be found at www.inc5000.com <http://www.inc5000.com> .
“Our second annual Inc. 5000 continues the most ambitious project in business journalism,” said Inc. 5000 project manager Jim Melloan. “The Inc. 5000 gives an unrivaled portrait of young, underreported companies across all industries doing fascinating things with cutting-edge business models, as well as older companies that are still showing impressive growth.”
ProTrials recently ranked seventh on the Silicon Valley/San Jose Business Journal’s list of the area’s Top 50 Women-Owned Businesses for 2008. This year, it attained certification by the Women’s Business Enterprise National Council, an elite group of women-owned and operated businesses.
About ProTrials Research, Inc.
Founded in 1996, ProTrials Research, Inc. is a specialized contract research organization (CRO) with regional clinical research associates and project managers based throughout North America, Canada, and Europe. The company works with clients in the pharmaceutical, biotechnology and medical device industries, providing cost-effective site monitoring, project management and associated clinical operations services. ProTrials is headquartered in Mountain View, California. For more information, visit www.protrials.com<http://www.protrials.com> or call (650) 864-9180.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.